Dupilumab for the Treatment of Alopecia Areata in Pediatric Patients with Atopic Dermatitis: A Scoping Review

This scoping review synthesizes evidence on the use of dupilumab for treating alopecia areata (AA) in pediatric patients with atopic dermatitis (AD). The study found that dupilumab treatment led to a significant mean reduction in SALT scores by 42.6 and a decrease in Investigator Global Assessment (IGA) levels by 2.14 units over an average of 3.21 months, indicating its efficacy in this patient group. The favorable safety profile of dupilumab in pediatric AD further supports its potential as a treatment option for AA. However, further research is needed to understand the underlying mechanisms, optimal patient selection, and long-term efficacy and safety of dupilumab in this context.